The U.S. Food and Drug Administration (FDA) recently released revised fact sheets for health care providers that include additional information on susceptibility of SARS-CoV-2 variants to each monoclonal antibody therapy available through an Emergency Use Authorization for COVID-19 treatment. The fact sheets contain details regarding specific variants and potential resistance. Download revised fact sheets for: Bamlanivimab; Bamlanivimab and Etesevimab and REGEN-COV™ (Casirivimab with Imdevimab).
